Phaseline

Companies › Blue Earth Therapeutics

Blue Earth Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lutetium (177Lu) rhPSMA-10.1 Injection
177Lu-labeled recombinant human PSMA-targeting radiopharmaceutical
PSMAPhase 1Prostate CancerMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05413850Lutetium (177Lu) rhPSMA-10.1 InjectionPhase 1Prostate CancerOncologyMar 2028

Targets

PSMA (1)

Companies with the same targets

Clarity Pharmaceuticals C Ray Therapeutics Nova Therapeutics Eli Lilly Fusion Pharmaceuticals Lantheus Medical Imaging Sinotau Pharmaceutical Group Norroy Bioscience Inovio Pharmaceuticals Curium US

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.